10-Q: Coherus Oncology Reports Q1 2026 Results, LOQTORZI Sales Grow

Coherus Oncology, Inc. reported first quarter 2026 results, with net revenue from continuing operations increasing to $12.3 million, driven by LOQTORZI sales growth.

Summary

• Coherus Oncology, Inc. reported first quarter 2026 results, with net revenue from continuing operations reaching $12.3 million, a significant increase from $7.6 million in the prior year period.
• The growth in net revenue was primarily attributed to increased sales volume of LOQTORZI, which generated $11.8 million in revenue.
• Cost of goods sold increased to $3.8 million, resulting in a gross margin of 69%, up from 65% in the prior year.
• Research and development expenses decreased to $21.5 million from $24.4 million, attributed to lower internal costs and reduced manufacturing-related development.
• Selling, general, and administrative expenses also decreased to $23.1 million from $26.0 million, due to lower headcount and operating costs following the divestiture of biosimilar businesses.
• The company reported a net loss from continuing operations of $36.9 million, an improvement from a net loss of $47.4 million in the prior year.
• As of March 31, 2026, the company had $167.0 million in cash, cash equivalents, and marketable securities.
• The company believes its available capital will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with revenue growth for LOQTORZI being a key positive, but the continued significant net loss and accumulated deficit remain substantial concerns.

Positives

• Net revenue from continuing operations increased by 62% to $12.3 million in Q1 2026 compared to $7.6 million in Q1 2025.
• LOQTORZI net revenue grew by 60.5% to $11.8 million.
• Gross margin improved to 69% from 65% in the prior year.
• Research and development expenses decreased by 11.5% to $21.5 million.
• Selling, general, and administrative expenses decreased by 11.2% to $23.1 million.
• Net loss from continuing operations improved to $36.9 million from $47.4 million.
• Cash, cash equivalents, and marketable securities stood at $167.0 million as of March 31, 2026.
• The company expects sufficient liquidity for at least the next twelve months.

Negatives

• The company continues to incur significant net losses from continuing operations ($36.9 million in Q1 2026).
• The accumulated deficit stands at $1.4 billion as of March 31, 2026.
• The company is still heavily reliant on future product sales and potential fundraising to sustain operations.
• Net revenue from discontinued operations was negative $0.9 million in Q1 2026, primarily due to changes in provisions related to prior year sales.

Risks

• The company has a limited history of profitability and may not achieve profitability again.
• Future net losses are expected due to substantial investments in research and development and commercialization.
• The commercial success of LOQTORZI and future product candidates depends on market acceptance, pricing, and reimbursement.
• The company faces intense competition from other immuno-oncology biologics.
• Healthcare reform measures, such as the Inflation Reduction Act, may impact the difficulty and cost of obtaining marketing approval and commercializing products.
• The company is highly dependent on key executives and personnel.
• Reliance on third-party contract manufacturers and CROs introduces risks related to quality, supply, and regulatory compliance.
• Manufacturing risks, including the transition to an onshoring business model, could increase costs and limit supply.
• Product candidates may cause undesirable side effects, potentially delaying or preventing regulatory approval or limiting commercial profiles.
• Infringement of third-party intellectual property rights could harm the business.
• The company may not be able to obtain or maintain adequate third-party coverage and reimbursement for its products.
• The company may need to raise additional funds in the future, with no assurance of success or favorable terms.
• The company is subject to manufacturing risks and the risk of inaccurately forecasting sales.
• The continuation of geopolitical conflicts may exacerbate existing risks.

Future Outlook

The company expects net revenue from continuing operations in 2026 to be higher than in 2025 due to continued growth of LOQTORZI. Fixed R&D expenses are expected to be lower in 2026 than in 2025 due to reduced expenditures on manufacturing-related development and headcount. SG&A expenses are also expected to be lower in 2026 than in 2025 due to decreased operating costs and headcount. Interest expense is expected to be slightly lower in 2026 than 2025.

Management Comments

• We believe that our available cash, cash equivalents and marketable securities, and product sales will be sufficient to fund our planned expenditures and meet our obligations for at least the twelve months following our financial statement issuance date.
• We expect net revenue from continuing operations in 2026 to be higher than in 2025 because of continued growth of LOQTORZI.
• We expect our fixed research and development expenses in 2026 to be lower than in 2025 primarily due to lower expenditures on manufacturing-related development activities and reduced headcount.
• The decrease in selling, general, and administrative expenses from continuing operations in the three months ended March 31, 2026 was primarily driven by a lower average headcount and decreased operating costs following our 2025 exit from the biosimilar business.

Industry Context

StockSavvy.ai notes that Coherus Oncology's Q1 2026 results reflect the ongoing transition from a biosimilar-focused company to an innovative oncology player with LOQTORZI as its lead commercial product. The growth in LOQTORZI revenue is a positive sign in a competitive immuno-oncology market, but the company's continued net losses and substantial accumulated deficit highlight the inherent risks and capital intensity of drug development and commercialization.

Legal Proceedings

• There are no pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries' property is subject.

Stakeholder Impact

• Shareholders: Continued net losses and reliance on future capital raises may impact stock value. Revenue growth from LOQTORZI is a positive indicator for future potential.
• Employees: The company's financial performance and R&D progress will influence job security and growth opportunities.
• Creditors: The company's liquidity and ability to service debt are key considerations for creditors.

Next Steps

• Continue to grow sales of LOQTORZI in Nasopharyngeal Carcinoma (NPC).
• Advance the development of two pipeline candidates in combination with LOQTORZI.
• Execute ex-U.S. licensing deals for clinical-stage candidates as clinical data supports.
• Continue post-marketing commitment study for LOQTORZI in advanced NPC.
• Junshi Biosciences is enrolling patients in a Phase 3 clinical study of LOQTORZI with its anti-BTLA antibody in LS-SCLC.
• INOVIO Pharmaceuticals plans a Phase 3 study of INO-3112 and toripalimab in HPV-positive oropharyngeal squamous cell carcinoma.
• Cancer Research Institute is evaluating toripalimab in combination with ENB Therapeutics' agent in a Phase 2 trial for ovarian cancer.
• STORM Therapeutics is evaluating its METTL3 inhibitor in combination with LOQTORZI in a Phase 1b/2 study for lung and head and neck cancers.
• Evaluate tagmokitug in combination with pasritamig in a Phase 1b clinical study in metastatic castration-resistant prostate cancer, expected to initiate in the fall.

Key Dates

Recommendation

The company shows revenue growth for its key product, LOQTORZI, and has improved its cost structure. However, the significant accumulated deficit and continued net losses, coupled with the inherent risks in drug development and competition, warrant a cautious approach. While the company has sufficient liquidity for the near term, future funding needs and the success of its pipeline remain critical factors. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustained revenue growth and a clearer path to profitability.

Keywords

Coherus Oncology, CHRS, Form 10-Q, Quarterly Report, LOQTORZI, Toripalimab, Oncology, Biotechnology, Financial Results, SEC Filing, Nasopharyngeal Carcinoma, Clinical Trials, R&D Expense, Net Revenue, Net Loss